US researchers develop new HPV - cancer vaccine
Moffitt Cancer Center researchers have developed a synthetic vaccine reported to be effective in treating human papillomavirus - derived cancer.
In an attempt to find an effective HPV-cancer vaccine, Esteban Celis and Kelly Barrios-Marrugo, from the University Of South Florida College Of Medicine's Molecular Medicine program, designed a peptide vaccination strategy called TriVax-HPV.
They believe there is a need to develop therapeutic vaccines for HPV - related tumors, as the two approved prophylactic vaccines currently used against the strains of HPV that cause cervical cancer to prevent its infections are ineffective in individuals with HPV - induced cancers.
According to the article published in a recent issue of Cancer Immunology, Immunotherapy, the newly designed vaccine can create strong immune responses in mice, with the additional benefit of not generating autoimmune - related pathologies.
" Vaccines for cancer can be good alternatives to conventional therapies that result in serious side - effects and are rarely effective against advanced disease, " said Celis who is also the senior member and professor in Moffitt ' s Immunology Program.
Researchers found the injection of TriVax with a small synthetic fragment(peptide) of the E۷ protein in mice with HPV۱۶ - induced tumors " induced tumor clearance in ۱۰۰ percent of the treated mice " while the unvaccinated mice with HPV - induced tumors had their tumors grow " at a fast rate. "
Human papillomavirus or HPV is known to cause 99 percent of cervical cancers and annually induces more than 250,000 deaths worldwide.